Montreal Protocol clear evidence of a decrease in the atmospheric burden of ozone-depleting substances and some early signs of stratospheric ozone recovery." However, a more recent study seems to point to a relative increase in CFCs due to an unknown source. Reported in 1997, significant production of CFCs occurred in Russia for sale on the black market to the EU throughout the 90s. Related US production and consumption was enabled by fraudulent reporting due to poor enforcement mechanisms. Similar illegal markets for CFCs were detected in Taiwan, Korea, and Hong Kong. . The Montreal Protocol is also expected to have effects on
Wiley protocol at separate times throughout the period. The protocol is promoted as differing from conventional hormone replacement therapy in several ways: The protocol also includes a follow-up program to monitor the serum of the bioidentical hormones. Wiley has stated that in her opinion, the most important aspect of the protocol is the specific schedule and levels of the hormone doses rather than their bioidentical nature. A patent was granted for the protocol in 2011 for the specific blend of hormones and dosing method. Concerns have been raised that serum levels may not be an acceptable marker for transdermally administered hormones, that